Invesco Pharmaceuticals ETF
PJP
117 hedge funds and large institutions have $98.8M invested in Invesco Pharmaceuticals ETF in 2026 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 34 reducing their positions, and 18 closing their positions.
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
2% less funds holding
Funds holding: 119 → 117 (-2)
10.3% less ownership
Funds ownership: 37.88% → 27.58% (-10%)
15% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 34
26% less call options, than puts
Call options by funds: $308K | Put options by funds: $415K
35% less capital invested
Capital invested by funds: $151M → $98.8M (-$52.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$1.83M |
| 2 |
Rockefeller Capital Management
New York
|
+$1.52M |
| 3 |
MML Investors Services
Springfield,
Massachusetts
|
+$1.25M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$1.05M |
| 5 |
QAM
Q3 Asset Management
Birmingham,
Michigan
|
+$645K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$23.9M |
| 2 |
Morgan Stanley
New York
|
-$18M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$4.93M |
| 4 |
CI
Cavalier Investments
Alpharetta,
Georgia
|
-$4.77M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.74M |
PJP Hedge Fund Activity: Q2 2026 in Review
117 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q2 2026, worth a combined $98.8M — down 35% from $151M a quarter earlier.
Fund positioning in PJP was balanced in Q2 2026: 18 funds opened new positions, 18 closed out, 29 added to existing stakes and 34 trimmed.
The largest buyer was Beacon Pointe Advisors, opening a new position worth an estimated $1.83M. The largest seller was HighTower Advisors, cutting an estimated $23.9M.
- 117 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q2 2026, down from 119 in Q1 2026.
- Funds reported $98.8M of Invesco Pharmaceuticals ETF stock for Q2 2026, down 35% quarter-over-quarter.
- 18 funds opened new Invesco Pharmaceuticals ETF positions in Q2 2026 and 18 closed out, a net change of 0 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q2 2026 was Beacon Pointe Advisors, an estimated $1.83M added.
- The largest Invesco Pharmaceuticals ETF seller in Q2 2026 was HighTower Advisors, an estimated $23.9M sold.
Based on aggregated 13F filings for Q2 2026.